George Dranitsaris

3.1k total citations
105 papers, 2.3k citations indexed

About

George Dranitsaris is a scholar working on Oncology, Economics and Econometrics and Surgery. According to data from OpenAlex, George Dranitsaris has authored 105 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 20 papers in Economics and Econometrics and 19 papers in Surgery. Recurrent topics in George Dranitsaris's work include Health Systems, Economic Evaluations, Quality of Life (15 papers), Cancer Treatment and Pharmacology (14 papers) and Bone health and treatments (11 papers). George Dranitsaris is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (15 papers), Cancer Treatment and Pharmacology (14 papers) and Bone health and treatments (11 papers). George Dranitsaris collaborates with scholars based in Canada, United States and United Kingdom. George Dranitsaris's co-authors include Justyna Bartoszko, Rabail Chaudhry, Talha Mubashir, Sheila Riazi, Eleftheria Hatzimichael, Eitan Amir, Aggeliki Dasoula, Konstantinos L. Bourantas, Leonidas Benetatos and Mark Vincent and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

George Dranitsaris

102 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George Dranitsaris Canada	28	774	449	355	350	313	105	2.3k
Claire Falandry France	26	1.2k 1.5×	338 0.8×	477 1.3×	343 1.0×	244 0.8×	109	3.1k
Matthew C. Cheung Canada	28	1.2k 1.5×	436 1.0×	210 0.6×	296 0.8×	210 0.7×	248	2.8k
Arjun Gupta United States	25	1.2k 1.5×	343 0.8×	388 1.1×	352 1.0×	293 0.9×	216	3.1k
Benoît You France	33	1.3k 1.7×	209 0.5×	713 2.0×	462 1.3×	284 0.9×	231	3.3k
Michael Montello United States	13	770 1.0×	227 0.5×	195 0.5×	102 0.3×	191 0.6×	26	2.0k
Carin A. Uyl‐de Groot Netherlands	34	1.5k 1.9×	889 2.0×	406 1.1×	436 1.2×	236 0.8×	217	3.7k
Bishal Gyawali Canada	32	1.3k 1.6×	1.6k 3.6×	319 0.9×	429 1.2×	509 1.6×	221	4.3k
Aurélien Latouche France	24	338 0.4×	253 0.6×	273 0.8×	129 0.4×	109 0.3×	62	2.2k
Sandra Eloranta Sweden	31	957 1.2×	180 0.4×	306 0.9×	412 1.2×	255 0.8×	125	3.1k
Kangmin Zhu United States	32	1.9k 2.5×	216 0.5×	695 2.0×	455 1.3×	468 1.5×	151	4.0k

Countries citing papers authored by George Dranitsaris

Since Specialization

Citations

This map shows the geographic impact of George Dranitsaris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Dranitsaris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Dranitsaris more than expected).

Fields of papers citing papers by George Dranitsaris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Dranitsaris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Dranitsaris. The network helps show where George Dranitsaris may publish in the future.

Co-authorship network of co-authors of George Dranitsaris

This figure shows the co-authorship network connecting the top 25 collaborators of George Dranitsaris. A scholar is included among the top collaborators of George Dranitsaris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Dranitsaris. George Dranitsaris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reingold, Rachel, Guilherme Harada, Andrea P. Moy, et al.. (2025). Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292). JTO Clinical and Research Reports. 6(3). 100792–100792. 1 indexed citations

Rossi, Anthony, Christian Menzer, Saud Aleissa, et al.. (2025). Platelet-Rich Plasma Treatment for Endocrine-Induced Alopecia and Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors: A Randomized, Controlled, Pilot Study. Dermatologic Surgery. 52(1). 41–47.

Gordan, Lucio, et al.. (2024). Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor. Current Oncology. 31(1). 501–510.

Dranitsaris, George, et al.. (2023). Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists. Alzheimer s Research & Therapy. 15(1). 60–60. 5 indexed citations

Dranitsaris, George, Mehdi M. Moezi, Katherine J. Dobson, Robert J. Phelan, & Sibel Blau. (2022). A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Supportive Care in Cancer. 30(8). 6649–6658. 3 indexed citations

Moezi, Mehdi M., et al.. (2022). The Safety and Efficacy of Fostamatinib in Patients with Chronic Immune Thrombocytopenic Purpura Treated in a Real-World Community Hematology Setting. Blood. 140(Supplement 1). 5135–5136. 2 indexed citations

Dranitsaris, George, Jonathan Thomas, Catherine Curran, et al.. (2021). An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 39(12). 834.e1–834.e7. 7 indexed citations

Chaudhry, Rabail, George Dranitsaris, Talha Mubashir, Justyna Bartoszko, & Sheila Riazi. (2020). A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. EClinicalMedicine. 25. 100464–100464. 263 indexed citations

Dranitsaris, George, Xiaofu Zhu, Georges Adunlin, & Mark Vincent. (2018). Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. Expert Review of Pharmacoeconomics & Outcomes Research. 18(4). 351–357. 41 indexed citations

10.

Gibson, Edward, George Dranitsaris, Danny Liew, et al.. (2018). Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. ClinicoEconomics and Outcomes Research. Volume 10. 139–154. 11 indexed citations

11.

Dranitsaris, George, et al.. (2017). Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness. Journal of Oncology Pharmacy Practice. 25(1). 68–75. 6 indexed citations

12.

Thavorn, Kednapa, Doug Coyle, Jeffrey S. Hoch, et al.. (2017). A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. Supportive Care in Cancer. 25(8). 2505–2513. 5 indexed citations

13.

Kuchuk, Iryna, Nathaniel Bouganim, Lisa Vandermeer, et al.. (2013). Patient perceptions about potential side effects and benefits from chemotherapy agents.. Journal of Clinical Oncology. 31(15_suppl). 6595–6595. 6 indexed citations

14.

Dranitsaris, George & Eleftheria Hatzimichael. (2012). Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Supportive Care in Cancer. 20(7). 1353–1360. 17 indexed citations

15.

Hilton, John, Lisa Vandermeer, Sean Hopkins, et al.. (2011). A multicenter study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH trial.. Journal of Clinical Oncology. 29(15_suppl). TPS242–TPS242. 1 indexed citations

16.

Dranitsaris, George, Peter Selby, & Juan Minango. (2009). Meta-Analyses of Placebo-Controlled Trials of Acamprosate for the Treatment of Alcohol Dependence. Journal of Addiction Medicine. 3(2). 74–82. 14 indexed citations

17.

Maroun, Jean A., Lowell Anthony, Normand Blais, et al.. (2007). Prevention and Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer: A Consensus Statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Current Oncology. 14(1). 13–20. 109 indexed citations

18.

Dranitsaris, George, et al.. (1999). Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Supportive Care in Cancer. 7(4). 271–279. 53 indexed citations

19.

Ortega, Ana, et al.. (1998). A Clinical and Economic Evaluation of Red Blood Cell Transfusions in Patients Receiving Cancer Chemotherapy. International Journal of Technology Assessment in Health Care. 14(4). 788–798. 14 indexed citations

20.

Dranitsaris, George, et al.. (1997). Cost-Benefit Analysis of Prophylactic Granulocyte Colony-Stimulating Factor During CHOP Antineoplastic Therapy for Non-Hodgkinʼs Lymphoma. PharmacoEconomics. 11(6). 566–577. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact